4 results about "Hepatic ischemia" patented technology

This invention relates to the field of biomedical materials technology and provides an application of obeticholic acid-exosome nanoparticles in the treatment of hepatic ischemia-reperfusion injury. The obeticholic acid-exosome nanoparticles are prepared by combining exosomes and obeticholic acid using an ultrasonic method, wherein the exosomes are derived from human bone marrow mesenchymal stem cells. The method for preparing the obeticholic acid-exosome nanoparticles is simple and easy to mass-produce. By utilizing exosomes derived from mesenchymal stem cells, the obeticholic acid-exosome nanoparticles improve the drug's targeting in vivo and prolong its circulation time, achieving targeted delivery of obeticholic acid to the liver, thus providing a new targeted therapeutic strategy for hepatic ischemia-reperfusion injury.

The application belongs to the field of biological medicine, and discloses application of echinocystic acid in preparation of a medicine for preventing and treating liver ischemia-reperfusion injury. The application proves that the echinocystic acid significantly improves liver tissue injury, reduces serum ALT and AST levels, and reduces cell apoptosis through a mouse liver IRI model. It is found that the echinocystic acid activates the p38 MAPK signal pathway by inhibiting PTPN1, thereby activating Nrf2 and enhancing PINK1 / Parkin-mediated mitochondrial autophagy. In addition, the echinocystic acid promotes DRP1 phosphorylation and enhances the transfer of DRP1 to mitochondria, thereby reducing oxidative stress and inflammatory response. It is shown that the echinocystic acid regulates mitochondrial autophagy through the PTPN1 / p38 MAPK / Nrf2 pathway, has a significant liver protection effect, and provides a new idea for the treatment of IRI.

This invention discloses a method for modifying lipid vesicles with an amphiphilic polymer containing N-oxide teramine groups. The amphiphilic polymer is OPDEA-PCL. OPDEA-PCL is used to modify synthetic liposomes, yielding amphiphilic polymer-synthetic liposome nanoparticles. OPDEA-PCL is also used to modify natural exosomes, yielding amphiphilic polymer-exosome nanoparticles. The amphiphilic polymer-synthetic liposomes of this invention possess active liver and lung targeting functions. This invention, through the engineered modification of exosomes with OPDEA-PCL, accurately guides exosomes to the liver regions requiring treatment, thereby enhancing the repair effect of exosomes on liver ischemia-reperfusion injury.

The use of 2,6-DMHQ in ischemia-reperfusion-related injuries, preferably against cardiac and hepatic ischemia-reperfusion injuries. 2,6-DMHQ can reduce serum ALT and AST and ameliorate liver necrosis. 2,6-DMHQ can also reduce the cardiac enzyme profile, including CK, CK / MB and LDH, and reduce myocardial infarct size.